Andrew Cittadine - Jun 18, 2024 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Role: Chief Operating Officer
Signature: /s/ Kim R Tsuchimoto, Attorney-in-fact
Stock symbol: MNPR
Transactions as of: Jun 18, 2024
Transactions value $: $25,574
Form type: 4
Date filed: 6/21/2024, 05:16 PM
Previous filing: Jun 17, 2024
Next filing: Jul 2, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MNPR	Common Stock	Purchase	$10.3K	+12K	+7.81%	$0.86	166K	Jun 18, 2024	Direct
transaction	MNPR	Common Stock	Purchase	$15.3K	+20.5K	+12.38%	$0.74	186K	Jun 20, 2024	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.73691 to $0.75860, inclusive. The reporting person undertakes to provide to Monopar Therapeutics, any security holder of Monopar Therapeutics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in the preceding sentence.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.73691 to $0.75860, inclusive. The reporting person undertakes to provide to Monopar Therapeutics, any security holder of Monopar Therapeutics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in the preceding sentence.